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Objectives:  The  authors  present  the  French  Society  of  Otorhinolaryngology  (SFORL)  guidelines
for histopathologic  assessment  of  head  and  neck  cancer.
Materiel  and  methods:  A  multidisciplinary  workgroup  set  up  by  the  SFORL  performed  an  exhaus-
tive review  of  the  literature  according  to  levels  of  evidence,  following  the  2000  guidelines  of
the French  national  health  approvals  and  assessment  agency  (ANAES).
Results:  Comparison  between  histologic  and  clinical  data  is  essential.  In  case  of  discrepancy
between clinical,  radiological  and  histological  ﬁndings,  reinterpretation  or  new  biopsy  may
be required  (professional  consensus).  Mere  suspicion  of  carcinoma  on  ﬁne-needle  aspiration
lymph-node  biopsy  only  exceptionally  warrants  aggressive  treatment  (professional  consensus).
Exploration  for  HPV  is  not  recommended  as  routine  practice,  being  without  therapeutic  impact
(professional  consensus).  Anti-p16  immunohistochemistry  is  optional,  for  epidemiological  pur-
poses (professional  consensus).  Tumor-bank  tissue  storage  must  conform  strictly  to  prevailing
legislation  and  good  practice  rules  for  sampling  and  preservation  (professional  consensus).
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Conclusion:  Pathology  assessment  is  mandatory  in  suspected  H&N  squamous  cell  carcinoma.
The present  guidelines  are  intended  to  optimize  management.





























































IThe  present  article  successively  deals  with  the  French
ociety  of  Otorhinolaryngology  (SFORL)  guidelines  for:
the  contents  of  histology  biopsy  reports,  and  their  role  in
the  management  of  head  and  neck  squamous  cell  carci-
noma;
 the  role  of  cytopathology  examination  in  initial  head  and
neck  cancer  assessment;
the interest  of  exploring  for  human  papilloma  virus  (HPV)
in  diagnostic  biopsy  of  head  and  neck  squamous  cell  car-
cinoma;
the  use  of  a  tumor  bank  in  initial  head  and  neck  cancer
assessment.
istology biopsy reports in the management of
ead and neck squamous cell carcinoma
natomopathology  reports  include  an  opening  section  com-
rising  administrative  and  clinical  data,  a  diagnostic  section
omprising  macro-  and  microscopic  description,  and  a
onclusion.  The  pathologist  is  responsible  for  their  presenta-
ion.  They  contain  information  that  is  essential  for  patient
anagement.  This  information  is  detailed  in  the  specialty
eference  documents.  Diagnosis  is  based  on  collating  the
vailable  clinical  and  biological  data.
eport  contents  (according  to  version  2,  2009)  of
he anatomy  and  cytopathology  good  practice
uidelines (RBPACP:  Référentiel  des  bonnes
ratiques en  anatomie  et  cyto-pathologiques  v2)
f the  French  Association  for  Quality  Assurance  in
natomy  and  Cytopathology  (AFAQAP:  Association
ranc¸aise d’assurance  qualité  en  anatomie  et
ytologie pathologiques)
he  report  ﬁrst  presents  administrative  and  clinical  data.
hese  are  partly  supplied  by  the  clinician  and  should  be  as
recise  and  informative  as  possible,  mandatorily  including:
 the  address  of  the  anatomy  and  cytopathology  (ACP)
structure;
 patient  identiﬁcation  (surname,  given  name(s),  date  of
birth,  PIN  or  other  registration  number);
type  of  sample  (ﬁne-needle  aspiration  biopsy?),  number
of  vials  sent  and  number  of  vials  received;
name  and  address  of  prescribing  physician;
if  possible,  names  and  addresses  of  corresponding  physi-
cians;
name  and  signature  of  the  reporting  pathologist;
 dates  of  sampling,  recording  and  reporting;
 ACP  structure  record  number;
c
t
d clinical  data  provided  by  the  biopsy  physician,  including
patient  history.
acro-  and  microscopic  description
he  report  is  intended  to  diagnose  any  malignancy,  guiding
he  clinician  with  regard  to  lesion  aggression.  Macroscopic
anagement  is  a  fundamental  stage.  It  should  be  stated
hether  samples  were  delivered  fresh  or  ﬁxed  and  if  any
pposition  or  freezing  was  performed;  whether  the  biopsy
elivered  is  oriented;  and  whether  extemporaneous  exami-
ation  had  been  performed.
In  diagnostic  biopsy,  macroscopic  examination  usually
onsists  in  specifying  the  number  and  size  of  the  samples.  If
he  biopsy  is  oriented,  resection  margins  should  be  tattooed
n  different  colored  inks,  respecting  specimen  orientation.
The  description  should  follow  a  logical  order:  either  that
f  the  vials  received  or  that  of  the  size  of  the  samples.  It
hould  include:
 conﬁrmation  of  inﬁltration;  description  of  dysplastic
lesions,  if  any;
 histologic  type,  if  possible  determining  whether  or  not
it  is  a  variant:  verrucous,  spindle-cell,  adenoid  or  acan-
tholytic,  basaloid,  papillary,  adenosquamous  or,  in  the
oral  cavity,  cuniculatum  squamous  cell  carcinoma  (Fig.  1);
 if  possible,  the  degree  of  differentiation  corresponding  to
the  histologic  grade:  well,  moderately  or  poorly  differen-
tiated;
 presence  of  nerve  sheathing  or  vascular  emboli:  although
often  difﬁcult  to  determine  on  biopsy,  should  be  reported
if  visible  [1—4].
As  well  as  the  carcinoma,  any  associated  lesions  (dys-
lasia,  etc.)  may  also  be  described,  and  especially  in  situ
arcinoma  lesions  (Fig.  2).  Two  precancerous  lesion  classiﬁ-
ations  (Table  1)  are  available,  to  be  selected  in  liaison  with
he  clinicians  [3,5].
Optionally  (and,  in  practice,  rarely),  inﬁltration  thickness
nd  inﬂammatory  inﬁltrate  data  may  be  provided.
Data  should  correspond  to  the  prevailing  guidelines
nd  recommended  classiﬁcations  [3].  Complementary  tech-
iques  (special  staining,  immunohistochemistry  and/or  in
itu  hybridization)  should  be  described  and  interpreted.
mmunostaining  is  rarely  needed  to  diagnose  squamous  cell
arcinoma;  in  relatively  undifferentiated  forms,  however,
otal  and/or  CK5/6  cytokeratin  expression  can  usefully  be
etected.
HPV  exploration  is  dealt  with  in  the  third  section.
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Figure  1  Invasive  squamous  cell  carcinoma:  some  histologic  variants.  A.  Conventional  squamous  cell  carcinoma.  B.  Basaloid
squamous cell  carcinoma.  C.  Spindle-cell  carcinoma.  D.  Verrucous  squamous  cell  carcinoma.
Figure  2  Dysplasia  and  invasive  squamous  cell  carcinoma  (HES  ×  40).  A.  Normal  malpighian  epithelium.  B.  Mild  to  moderate
dysplasia. C.  Severe  dysplasia/in  situ  carcinoma.  D.  Invasive  squamous  cell  carcinoma.
322  C.  Badoual  et  al.
Table  1  Precancerous  lesion  classiﬁcation.
World  Health  Organization  (WHO)  Hellquist  (Ljubljana)
Benign Simple  hyperplasia  Simple  hyperplasia
Abnormal  hyperplasia
Precancerous  with  low  risk  of  invasive
carcinoma
Dysplasia  grade  I Atypical  hyperplasia
Dysplasia  grade  II
Precancerous  with  high  risk  of
invasive  carcinoma
Dysplasia  grade  III  Carcinoma  in  situ













































reat  care  should  be  given  in  ﬁlling  out  the  pathology
equest  form.  So  far  as  possible,  a  diagnosis  should  be  sug-
ested  for  each  sample,  with  the  degree  of  proliferation
invasive,  in  situ). The  conclusion  should  provide  a  synthesis,
sing  national  and/or  international  classiﬁcations.  In  case  of
iscrepancy  between  clinical,  radiological  and  histological
ndings,  pathology  and  clinical  data  should  be  compared,
ith  possible  re-analysis  of  the  sample  or  complementary
ampling.
Histology  biopsy  reports  in  the  management  of  head
and  neck  squamous  cell  carcinoma:  SFORL  guidelines.
•  Great  care  should  be  given  in  ﬁlling  out  the  pathology
request  form  (professional  consensus).
• The  practitioner  should  check,  in  the  report,  the  var-
ious  carcinoma  characteristics,  and  especially  the
degree  of  invasion  (professional  consensus).
•  Pathology  and  clinical  results  should  be  compared,
and  sampling  be  renewed  or  re-analyzed  if  necessary,
after  discussion  with  the  pathologist  (professional
consensus).
ytopathology in initial assessment for  head
nd neck cancer
istologic  examination  to  conﬁrm  malignancy  is  mandatory
efore  initiating  treatment  of  head  and  neck  cancer.  When
o  mucosal  tumor  is  accessible  for  biopsy,  diagnosis  may
e  founded  on  cervical  adenopathy.  Two  types  of  samp-
ing  may  be  performed:  ﬁne-needle  lymph-node  aspiration,
hich  may  be  guided  by  imaging,  or  resection  biopsy  (ade-
oidectomy).  Indications  for  biopsy  by  trocar  or  lymph-node
urgical  biopsy  are  highly  controversial,  rarely  performed,
nd  are  no  longer  recommended  in  current  practice  (expert
onsensus).
Fine-needle  aspiration  cytology  is  a  simple,  inexpensive
nd  relatively  non-invasive  examination  enabling  differ-
ntial  cytologic  diagnosis  between  lymphoma,  metastasis
nd  chronic  adenitis  [6].  It  can  easily  be  performed  at
he  bedside  or  on  an  outpatient  basis.  False-positives  and




mn diagnosing  lymph-node  metastasis  from  squamous  cell
arcinoma  [7,8]. Slide  interpretation  is  highly  investigator-
ependent.  In  poorly  differentiated  tumor,  cell  typing  may
e  difﬁcult;  some  teams,  when  possible,  perform  comple-
entary  immunohistochemical  staining.
In  practice,  when  primitive  tumor  biopsy  is  not  feasible,
wo  situations  may  arise:
for  adenopathy  without  obvious  primitive  lesion  but  with
a  strong  clinical  suspicion  of  squamous  cell  carcinoma
metastasis,  in  which  clinical  assessment  (ENT  examina-
tion,  CT  and  PET)  failed  to  ﬁnd  the  primitive  tumor,
ﬁne-needle  aspiration  can  diagnose  malignancy  in  almost
90%  of  cases  [9].  Lymph-node  surgical  biopsy  is  contra-
indicated  as  worsening  the  rate  of  lymph-node  recurrence
and  metastasis  [10], with  a  risk  of  seeding  the  cutaneous
trajectory  [8].  The  logical  attitude  [11,12],  when  no  prim-
itive  tumor  is  found,  is  tonsillectomy  or  tonsil  biopsy  if
aspiration  indicates  squamous  cell  carcinoma  metastasis,
with  possible  exploratory  cervicotomy  and  extemporane-
ous  histologic  examination.  The  patient  should  be  advised
of  the  possibility  of  associating  lymph-node  curage  to  the
operation;
 if  the  patient’s  general  health  status  precludes  general
anesthesia  and  the  tumor  is  not  accessible  orally  or  by
ﬂexible  endoscopy,  diagnosis  requires  ﬁne-needle  aspi-
ration  cytology.  Biopsy  of  non-resectable  lymph-nodes,
by  trocar  or  surgery,  is  only  rarely  indicated  to  con-
ﬁrm  diagnosis  before  initiating  curative  or  palliative
treatment.
Fine-needle  aspiration  cytology  is  not  sufﬁcient  to  initi-
te  therapy,  but  contributes  to  guiding  assessment.  Before
ny  invasive  surgery  or  radiation  and/or  chemotherapy,
iagnosis  and  exact  histological  type  should  be  conﬁrmed
n  classic  histology  in  a  tumoral  or  lymph-node  biopsy
ample.
It should  be  stressed  that  interpreting  ﬁne-needle  aspi-
ation  samples  of  cervical  cysts,  especially  in  region  II,  is
ifﬁcult:  it  is  often  impossible  to  distinguish  between  a
econd-groove  (tonsillar)  cyst  and  cystic  metastasis  of  a
usually  oropharyngeal)  well-differentiated  squamous  cell
arcinoma.  It  should  be  borne  in  mind  that,  in  patients  over
0  years  of  age,  metastasis  is  more  likely  than  congenital
yst  and  that  histologic  examination  of  the  resection  speci-
en  is  required.
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Figure  3  In  situ  identiﬁcation  of  HPV  infection.  A.  Immunohistochemical  study  with  anti-p16;  the  tumor  cells  are  uniformly  stained
(cytoplasmic and  nuclear  staining).  B.  HPV  in  situ  hybridization  (onco
showing the  integration  of  the  virus  into  the  genome  (arrows).
Cytopathology  examination  in  initial  assessment  of
head  and  neck  cancer:  SFORL  guideline.
Mere  suspicion  of  squamous  cell  carcinoma  based
on  ﬁne-needle  lymph-node  aspiration  is  insufﬁcient  to























nchemotherapy)  (professional  consensus).
Role of  human papilloma virus (HPV)
exploration  in diagnostic biopsy of head and
neck squamous cell carcinoma
In  certain  (notably  oropharyngeal)  locations,  oncogenic  HPV
subtypes  (mainly  HPV16  and  HPV18)  may  be  the  only  environ-
mental  factors  found.  HPV  rates  reach  50  to  70%  in  tonsillar
cancer  [13—19]. These  small,  icosahedrically  symmetrical
non-enveloped  DNA  viruses  have  an  oncogenic  effect  medi-
ated  by  viral  proteins  E6  and  E7,  respectively  disturbing  the
functioning  of  tumor-suppressor  genes  p53  and  pRb.
Epidemiological  data  show  that  the  HPV  rates  depend  on
tumor  location,  predominating  in  oropharyngeal  sites  (ton-
sil  and  tongue  base),  and  on  the  patient’s  geographic  origin,
with  the  highest  prevalence  in  Europe  being  in  Scandina-
vian  countries.  In  France,  the  single  retrospective  study  to
be  published,  involving  12  hospital  centers  and  523  orop-
haryngeal  or  oral  cavity  biopsies,  found  HPV  in  46.5%  of
oropharyngeal  and  10.5%  of  oral  cavity  squamous  cell  carci-
nomas  [20].Several  cohort  studies  conﬁrmed  presence  of  HPV  in  at
least  30%  of  tonsil  cancers.  HPV  prevalence  in  5046  head
and  neck  squamous  cell  carcinomas  (all  locations  taken
T
r
rgenic  HPV  cocktail).  The  tumor  cells  are  stained  in  the  nucleus,
ogether)  was  25.9%  [16]; oropharyngeal  locations  (35.6%  of
PV-associated  cancers)  were  more  frequent  than  the  oral
avity  (23.5%)  or  larynx  (24%).
In head  and  neck  squamous  cell  carcinomas,  HPV  seems  to
e  associated  with  better  radio-  and  chemosensitivity,  and
s  a  factor  of  good  prognosis  in  terms  of  survival  [13,21—23].
Oncogenic  HPV  infection  may  thus  serve  as  a  major
iological  marker,  both  therapeutically  and  prognostically.
t  is  therefore  increasingly  important  to  screen  for  onco-
enic  viruses,  using  reliable  tools,  so  as  better  to  adapt
reatment  by  better  understanding  of  the  virus-induced
icro-environment.
Virologic  exploration  uses  PCR  on  a  tumor  fragment,
resh,  frozen  or  included  in  parafﬁn,  or  in  situ  hybridization
y  DNA  probe  on  material  included  in  parafﬁn  (usually  with  a
ocktail  corresponding  to  the  most  frequent  HPV  oncogenes)
24,25].
In  immunohistochemistry,  p16  overexpression  by  the
umor  is  an  indirect  marker  of  HPV  (Fig.  3).  However,  anti-
16  antibody  staining  needs  to  be  correctly  interpreted
diffuse  staining  of  the  majority  of  tumor  cells)  [26]; more-
ver,  p16  overexpression  may  also  be  found  in  certain
PV-negative  squamous  cell  carcinomas  on  in  situ  hybridiza-
ion  or  PCR.  With  or  without  association  with  HPV,  p16
verexpression  is  a  factor  of  fairer  prognosis  [27—29].
umor banks: guidelines in initial head and
eck cancer assessmentumor  cryopreservation  banks  were  initially  set  up  for
esearch  purposes,  and  are  now  indispensable  tools  in  cancer
esearch.  Patients  with  one  or  more  cryopreserved  sample
324  
Role  of  human  papilloma  virus  (HPV)  exploration  in
diagnostic  biopsy  of  head  and  neck  squamous  cell  car-
cinoma:  SFORL  guidelines.
•  HPV  should  not  be  researched  for  systematically,  in
absence  of  therapeutic  impact  (professional  consen-
sus).
• In  the  particular  case  of  oropharyngeal  carcinoma
and/or  patients  free  of  smoking  and  alcohol  risk  fac-
tors,  immunohistochemistry  with  anti-p16  antibody


























































































by  a  qualiﬁed  physician  and  conﬁrmed  by  duplicate  signedsional  consensus).
re  listed  in  a  computerized  data  ﬁle  which,  in  accordance
ith  French  public  health  law,  is  submitted  to  the  health
esearch  data  processing  consultative  committee,  as  stip-
lated  in  article  40-2  of  Act  no 78-17  of  January  6,  1978
oncerning  computerized  data  ﬁles  and  liberty;  as  stipulated
n  the  Civil  Code  (articles  16-1  and  16-6),  the  samples  may
ot  be  sold  and  patients  receive  no  payment.
Just  as  a  bank  holds  money  and  a  blood-bank  conserves
lood  samples,  a  tumor  bank  conserves  tumor  fragments.
ver  time,  as  well  as  tumor  fragments  and  serum  samples,
ragments  of  healthy  tissue  (exposed  to  toxins  or  not),  skin,
odes,  and  exfoliated  cells  in  saliva  are  also  sampled  for
 given  patient:  the  term  ‘‘biological  collection’’  or  ‘‘bio-
ank’’  is  in  fact  more  apt  than  ‘‘tumor  bank’’,  which  is
ather  reductive;  to  avoid  confusion,  however,  the  term
‘tumor  bank’’  will  be  used  hereinafter.  Conservation  and
se  of  biological  material  has,  since  the  bioethics  law  of
ugust  6,  2004,  been  strictly  controlled  by  laws  and  regula-
ions,  themselves  partly  founded  on  EU  provisions  (notably,
irective  2004-23  of  March  31,  2004,  amended  by  Decree
007-1220  of  August  2007).  Moreover,  good  practice  guide-
ines  have  been  progressively  developed  in  this  ﬁeld.
There  are  tumor  banks  for  health  purposes,  comprising
amples  stored  for  diagnostic  and/or  prognostic  purposes
r  for  therapeutic  decision-making,  based  on  investiga-
ions  requiring  frozen  material.  In  2006,  the  French  hospital
dmission  and  care  organization  authority  (Direction  de
’hospitalisation  et  de  l’organisation  des  soins: DHOS)  and
ational  cancer  institute  (Institut  national  du  cancer: INCA)
et  up  an  expert  group  to  determine  which  tumors  should
e  sampled  in  health-service  tumor  banks  [30]. The  tumors
elected  were:  malignant  hemopathies,  sarcomas,  brain
umors  and  childhood  tumors.  Some  colorectal  and  pul-
onary  tumors  initially  selected  were  later  excluded  under
he  new  2011  INCA  guidelines  (Tumor-bank  indications  and
uidelines  update,  available  on  the  INCA  website).  Head  and
eck  tumors  are  thus  not  included.  The  experts’  choice,
owever,  was  a  snapshot  of  the  state  of  knowledge  in
olecular  and  tumoral  pathology,  obviously  requiring  con-
tant  updating.  Moreover,  the  same  expert  group  strongly
ecommended  that,  whenever  possible,  a  sample  of  any
alignant  tumor  should  be  cryopreserved  for  research  pur-
oses,  including  retrospective  studies.  Abnormalities  of
ecognized  health  interest  concern  DNA  and  are  represented
y  gene  rearrangement,  translocation,  ampliﬁcation,  dele-
ion  and  mutation,  shown  on  direct  DNA  or  RNA  study.  MoreC.  Badoual  et  al.
xceptionally,  abnormal  quantitative  expression  may  be  of
nterest.  Interest  may  be  diagnostic  or  therapeutic.  If  such
bnormalities  are  detected  in  one  or  more  head  and  neck
umor  subtypes,  a  health  tumor  bank  should  be  set  up.  At
resent,  cryopreservation  is  not  mandatory  for  head  and
eck  tumors,  regardless  of  location.
hich  physicians  are  concerned?
ny  physician  or  surgeon,  in  the  public  or  private  sector,  may
ecide  to  cryopreserve  a  head  and  neck  tumor  fragment.  If
he  practitioner  is  remote  from  any  tumor  bank,  an  agree-
ent  on  inter-institution  sample  management  needs  to  be
rawn  up.
hich  tumors  should  be  sampled?
or  head  and  neck  tumors,  no  law  or  professional  guide-
ines  specify  which  are  to  be  sampled.  Targeting  is  usually
p  to  hospital  teams  doing  research  in  head  and  neck  tumor
iology,  depending  on  their  line  of  research.
lace  of  sample  storage
n  practice,  tumor  banks  tend  to  be  located  in  health  struc-
ures  and  particularly  in  biological  resource  centers.  The
rganization  requesting  cryopreservation  should  ﬁrst  submit
he  project  to  a  Committee  of  Protection  of  the  Individual
Comité  de  protection  des  personnes:  CPP)  for  approval,
hen  make  a declaration  to  the  Ministry  of  Research  and
o  the  director  of  the  relevant  regional  health  authority
o  obtain  authorization  according  to  article  L-1243-C  of
he  Public  Health  Code.  Hospital  tumor  banks  come  under
he  2006  good  practice  rules  for  clinicians  and  researchers
rawn  up  by  INCA  in  cooperation  with  Inserm,  the  Paris
P—HP  hospitals  board  and  the  national  cancer  center
ederation  (CLCC),  one  of  the  ‘‘professional  guidelines’’
ublished  by  INCA  and  available  at  http://www.e-cancer.fr/
xpertises-publications-de-l-inca/rapports-et-expertises/
echerche  under  ‘‘Conservation  et  utilisation  des  échantil-
ons  tumoraux  en  cancérologie’’ (conservation  and  use  of
umor  samples  in  oncology).  Part  of  the  collection  may  be
iven  over  to  another  organization  (mainly,  research  teams)
or  scientiﬁc  use,  either  free  of  charge  or  in  exchange  for
ayment  after  approval  by  the  tumor  bank  management
nd  the  scientiﬁc  committee  of  the  Biological  Resources
enter  or  Platform.
ood  practice  rules
he  French  Health  Authority  (HAS)  guidelines  (available  on
he  HAS  website,  under  ‘‘Cryopréservation’’) are:
 it  is  necessary  to  inform  the  patient  and  be  sure  there  is  no
opposition  to  the  biological  samples  being  used  for  non-
diagnostic  purposes;  the  information  should  be  deliveredwritten  consent,  one  copy  given  to  the  patient  and  the
other  kept  in  the  medical  ﬁle;  the  consent  form  should














[Recommendations  of  the  French  Society  of  Otorhinolaryngol
addresses;  it  should  be  speciﬁed  that  the  patient  may  at
any  time  demand  that  his  or  her  samples  be  destroyed;
a  separate  speciﬁc  consent  form  is  to  be  provided  to  and
signed  by  the  patient  in  case  of  genomic  identiﬁcation;
•  it  is  important  that  tumor  samples  be  frozen  as  quickly
as  possible  (within  15  minutes,  if  possible)  to  ensure  good
nucleic  acid  conservation;  sampling  should  be  from  a  non-
necrotic  region  of  the  tumor,  using  sterile  material;  the
sample  should  be  taken  quickly  to  the  pathology  depart-
ment  for  freezing,  or  be  immediately  placed  in  RNA-later
medium  to  allow  transport  at  room  temperature  as  soon  as
possible  (especially  suitable  in  the  private  sector);  after
conditioning  in  the  pathology  department,  the  sample  is
to  be  taken  for  storage  in  the  biological  resources  center;
• a  ‘‘mirror’’  inclusion  block  (corresponding  to  the  other
face  of  the  frozen  sample)  should  be  systematically  cre-
ated  for  the  sample;  stained  slides  are  to  be  stored  in  the
pathology  department;
• an information  sheet  concerning  the  sample  and  a  copy  of
the  pathology  report  should  be  sent  to  the  tumor  bank;
• non-tumor  samples  (blood,  saliva,  healthy  tissue,  etc.)
should  be  taken  in  the  same  step  and  undergo  speciﬁc
conditioning,  transport  and  storage;
• cryopreservation  is  a  medical  act,  and  should  be  per-
formed  by  a  pathologist,  or  possibly  delegated  to  a
laboratory  technician,  but  only  under  the  supervision  of  a
pathologist;
• the  stored  sample  may  be  used  for  studies  based  on
nucleic  acids  or  proteins;  the  biological  resources  cen-
ter’s  technical  facilities  should  be  adapted  to  the  study
to  be  undertaken.
Tumor  banks:  SFORL  guidelines.
Any  tumor-bank  storage  must  respect  prevailing  leg-
islation,  especially  as  regards  informed  consent,  and
scrupulously  follow  good  practice  rules  for  sampling
and  storage  (professional  consensus).
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